linjc16/ctgov huggingface dataset:
Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive Episode

Study Overview
=================
Brief Summary
-----------------
This is a prospective open label study of acute and maintenance treatment of MDD. The acute phase consists of daily treatments for 4 weeks. maintenance will be twice a week for eight weeks followed by 10 weeks of once a week treatments.

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Device: H-coil dTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MDD patients Exclusion Criteria: risk factors for convulsions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: depressive patients<br>patients suffering from deppresion | Device: H-coil dTMS<br>* treatment with deep TMS stimulation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| response in HAMDS |  | 1 YEAR | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MOOD EVALUATION
Detection of Tumor DNA Through Cervical Smear and Liquid Biopsy in Endometrial Cancer Patients and Evaluation of Prognostic and Predictive Values of Tumor DNA Assay

Study Overview
=================
Brief Summary
-----------------
Circulating tumor DNA (ctDNA) may help detect and prognosis-stratify patients with endometrial cancer. Both cervical swab-based genomic DNA (gDNA) and whole blood-based ctDNA can be utilized for this goal. Our objective is to utilize cervical swab and whole blood samples to analyze tumor-derived ctDNA from patients with endometrial cancer. These samples will be collected prospectively, and prior to staging operation. Samples from patients without cancer, who undergo hysterectomy for benign gynecological cause, will be utilized as controls. Variants called by next generation sequencing were classified into four-tiers based on ASCO/AMP system. These initially captured samples will be used to compare performance in terms of detection rate and to stratify patients based on the mutational profile. Additionally, in patients with advanced disease, we plan to collect whole blood samples every 3 months to assess any changes in mutational landscape. Clinical data including age, cormorbidities, treatment methods, date of diagnosis and recurrence, response evaluation for chemotherapy or radiotherapy, survival data will be used to contextualize our findings.

Official Title
-----------------
Detection of Tumor DNA Through Cervical Smear and Liquid Biopsy in Endometrial Cancer Patients and Evaluation of Prognostic and Predictive Values of Tumor DNA Assay

Conditions
-----------------
Endometrial Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, over 19 years of age Patients with endometrial cancer or benign gynecological diseases Exclusion Criteria: Patients in pregnancy Patients being treated for cancer of other organs, including gynecological cancer. Patients who has difficulty reading and understanding Korean. The tester's determination that the patient will not be able to comply with the clinical trial procedures. Patients with severe infections or other serious medical problems that have resulted in impairment of the patient's function, making it difficult to the trial.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endometrial cancer group<br>Patients pathologically diagnosed with endometrial cancer | |
| Control group<br>Patients with benign endometrial pathology and interepithelial neoplasia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection rate | We aim to compare the ctDNA mutation detection rate based on cervical swab and whole blood at the time of surgery. | Detection rate based on two different modalities at the time of surgery. |
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Study Overview
=================
Brief Summary
-----------------
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Three Fixed Doses (100 Mg, 200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Drug: DVS-233 SR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients Sexually active women participating in the study must use a medically acceptable form of contraception Subjects must have a primary diagnosis of major depressive disorder Exclusion Criteria: Treatment with DVS-233 SR at any time in the past Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 Known hypersensitivity to venlafaxine (IR or ER)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: DVS-233 SR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depressive Disorder, Major, Melancholia, Involutional, Depression, Involutional
The Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effect of hospital admission on 24-hour ambulatory blood pressure (ABP) in hypertensive subjects.Treated or untreated hypertensive adults with open angle glaucoma underwent in-hospital and outpatient 24-hour ABP monitoring, in random order 4 weeks apart.

Official Title
-----------------
A Study Investigating the Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure in Subjects With Mild to Moderate Arterial Hypertension and Untreated Ocular Hypertension

Conditions
-----------------
Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age >30 years old. subject has signed an informed consent. patient has untreated ocular hypertension (IOP at 10:00 between 22-34 mm Hg) patient has stage 1 arterial hypertension with or without therapy Exclusion Criteria: secondary hypertension. stage 2 or 3 hypertension, history of renal disease. sleep apnea. diabetes mellitus acute or chronic inflammation. myocardial infarction or unstable angina within the past 6 months. heart failure NYHA class III-IV. active liver disease. pregnancy. history of drug or alcohol abuse, or any other condition with poor prognosis. treatment with non-steroid anti-inflammatory agents, corticosteroids, beta-blockers, or any other regimen that could affect BP levels. smoking

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Ambulatory measurement
SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Study Overview
=================
Brief Summary
-----------------
Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction

Official Title
-----------------
A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Aliskiren


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 20 - 80 years old Gender: Male or female Status: Outpatients Elevated Serum Creatinine Exclusion Criteria: Patients suspected of malignant hypertension Patients with a clinically significant allergy Patients who have received other investigational drug Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aliskiren|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events after 8 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean sitting systolic blood pressure after 8 weeks |  |  | 
| Change from baseline in mean sitting diastolic blood pressure after 8 weeks |  |  | 
| Mean sitting systolic blood pressure is < 140 mmHg or a reduction of > 20 mmHg after 8 weeks |  |  | 
| Mean sitting diastolic blood pressure is < 90 mmHg or a reduction of > 10 mmHg after 8 weeks |  |  | 
| Blood pressure <140/90 after 8 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, aliskiren, blood pressure, rennin
Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis

Study Overview
=================
Brief Summary
-----------------
To evaluate the effects of exogenous selenium supplementation on autoimmune thyroiditis.

Detailed Description
-----------------
In patients with autoimmune thyroiditis， investigators compared changes in thyroid function, anti-thyroid peroxidase antibody, anti-thyroglobulin antibody, thyroid magnetic resonance T1-mapping values and metabolic indicatorsfrom baseline to the end of treatment (12 weeks)

Official Title
-----------------
Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis

Conditions
-----------------
Selenium

Intervention / Treatment
-----------------
* Drug: Selenium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or women between the ages of 18 and 75 Clinical diagnosis of autoimmune thyroiditis, serum TPOAb and TGAB positive Thyroid function is normal, and no drugs affecting thyroid function such as Umetole and Serge have been used Exclusion Criteria: The contraindications indicated in the Chinese instructions of the drug Hypothyroidism, hyperthyroidism Liver function impairment Renal function impairment Claustrophobia Mental disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: patients with Autoimmune thyroiditis
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: selenium<br>selenium was administered to patients with autoimmune thyroiditis | Drug: Selenium<br>* selenium 100ug ，take it orally twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anti-thyroglobulin antibody changes | Changes from baseline and 3 months during follow-up | Changes from baseline and 3 months during follow-up | 
| T1-mapping values of Thyroid MRI | Changes from baseline and 3 months during follow-up | Changes from baseline and 3 months during follow-up |
Tumor RNA Transfected Dendritic Cell Vaccines

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

Detailed Description
-----------------
The specific aims are: 1) to evaluate, in a phase I clinical trial, the safety of vaccinating patients with dendritic cells transfected with RNA from autologous cancer cells; 2) to analyze the T cell responses induced by the treatment; and 3) to improve the efficacy of the treatment by developing methods to increase the induction of CD4+T cell responses.

Official Title
-----------------
Tumor RNA Transfected Dendritic Cell Vaccines

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Biological: Tumor RNA transfected dendritic cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a histologically confirmed diagnosis of metastatic prostate cancer stages D1 - D3 are eligible for this study. They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy. Exclusion Criteria: Patients will be excluded from the study if they have received chemotherapy or other forms of immunotherapy in the 6 weeks prior to study entry.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Tumor RNA transfected dendritic cells|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostatic Neoplasms, Neoplasm Metastasis, Immunotherapy, Active, Dendritic Cells
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Official Title
-----------------
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.

Conditions
-----------------
Tumors, Neoplasms

Intervention / Treatment
-----------------
* Drug: TTI-237


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of malignant solid tumor with measurable disease Life expectancy of at least 12 weeks ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2 Exclusion Criteria: Recent major surgery, radiation therapy or anti-cancer treatment History of any other prior malignancy within the last 5 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: TTI-237|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preliminary pharmacokinetics (during cycle 1) and anti-tumor activity of TTI-237 (approximately every 8 weeks). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Malignant Solid Tumors
Aggreguide A-100 ADP Assay Evaluation

Study Overview
=================
Brief Summary
-----------------
The study is to characterize the AggreGuide ADP Assay's performance.

Official Title
-----------------
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument

Conditions
-----------------
ADP Blockers, Platelet Aggregation

Intervention / Treatment
-----------------
* Other: platelet aggregation measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-75 Exclusion Criteria: less than 60 kg on antiplatelet meds other than aspirin antiplatelet drugs contraindicated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ADP Blockers<br>platelet aggregation in response to antiplatelet drugs | Other: platelet aggregation measurement<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Platelet Activity Index (PAI) | PAI at baseline and after taking ADP blocking antiplatelet drugs. | 1 week |
Parkinson's Foundation Surveys

Study Overview
=================
Brief Summary
-----------------
Parkinson's Foundation Surveys is an initiative seeking to periodically survey people with Parkinson's disease (PD), their care partners and medical professionals to better understand specific aspects of living with PD.

Official Title
-----------------
Parkinson's Foundation Surveys

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Other: Non-interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willingness to be contacted by the Parkinson's Foundation for surveys and any future research opportunities Anyone who self-reports that they have a diagnosis of Parkinson's disease Care partner of a person with Parkinson's disease Any health professional that regularly works with people with Parkinson's disease 18 years of age or older Exclusion Criteria: People who report that they do not have a diagnosis of Parkinson's disease, are not a care partner to someone with PD or do not work with people with PD in the health setting An individual younger than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| People with Parkinson's disease<br> | Other: Non-interventional<br>* non-interventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total number of survey respondents | Total number of survey participants who consent into the study | 10 years |